Berberine activates peroxisome proliferator-activated receptor gamma to increase atherosclerotic plaque stability in Apoe\(^{-/-}\) mice with hyperhomocysteinemia

Hongjun Li\(^1\), Chengyan He\(^1\), Jingying Wang\(^1\), Xiaou Li\(^2\), Zhaowei Yang\(^1\), Xiaoying Sun\(^1\), Ling Fang\(^1\), Ning Liu\(^3\)*

\(^1\)China-Japan Union Hospital, Jilin University, \(^2\)Tumor Hospital of Jilin Province, and \(^3\)Central Laboratory, The Second Hospital of Jilin University, Changchun, China

**Keywords**
Atherosclerosis, Berberine, Peroxisome proliferator-activated receptor-\(\gamma\)

\*Correspondence
Ning Liu
Tel.: +86-431-8879-6555
Fax: +86-431-8879-6852
E-mail address: liu_ning@jlu.edu.cn

J Diabetes Investig 2016; 7: 824–832
doi: 10.1111/jdi.12516

**ABSTRACT**

**Aims/Introduction:** An elevated level of plasma homocysteine has long been suspected as a metabolic risk factor for the development of atherosclerotic vascular diseases in diabetes. Berberine (BBR) has several preventive effects on cardiovascular diseases. The effects of BBR on atherosclerotic plaque stability increased by homocysteine thiolactone (HTL) remain unknown.

**Materials and Methods:** The model of atherosclerotic vulnerable plaque was induced by placing a collar around the carotid artery in Apoe\(^{-/-}\) mice. Endothelium-dependent relaxation was assayed by organ chamber.

**Results:** Homocysteine thiolactone (50 mg/kg/day, 8 weeks) reduced the atherosclerotic plaque stability in the carotid artery of Apoe\(^{-/-}\) mice, which was reversed by BBR administration (1.0 g/kg/day). In vivo and ex vivo experiments showed that HTL dramatically reduced acetylcholine-induced endothelium-dependent relaxation and superoxide dismutase activity, and increased malondialdehyde content, which were inhibited by BBR. Importantly, all effects induced by BBR were abolished by GW9662, an antagonist of peroxisome proliferator-activated receptor-\(\gamma\). Incubation of cultured endothelial cells with HTL significantly reduced cell viabilities and enhanced production of reactive oxygen species. Pretreatment of cells with BBR dose-dependently reversed HTL-induced detrimental effects, which were GW9662-reversible.

**Conclusions:** Berberine increases atherosclerotic plaque stability in hyperhomocysteinemia mice, which is related to the activation of peroxisome proliferator-activated receptor-\(\gamma\) and subsequent suppression of oxidative stress in endothelial cells.

**INTRODUCTION**

Atherosclerotic coronary artery disease, the underlying basis for ischemic heart disease, is the leading cause of death and disability in diabetes patients\(^1,2\). Moderate hyperhomocysteinemia (HHCY) has been observed in some studies of diabetic patients with atherosclerosis. The homocysteine levels reflect the nature of the patients studied, including patients with poor glycemic control, variable duration of diabetes, and a variety of microvascular and macrovascular complications\(^3\). HHCY might play a role in the pathogenesis of vascular disorders, and is considered as an independent risk factor for atherosclerosis\(^4\).

Homocysteine occurs in human blood plasma in several forms, including the most reactive one, which is homocysteine thiolactone (HTL) of a cyclic trimester, and represents up to 0.29% of total plasma homocysteine\(^5\). HTL reacts with proteins by acylation of free basic amino groups. In particular, the epsilon-amino group of lysine residues forms adducts, and induces structural and functional changes in plasma proteins. High levels of homocysteine impair endothelial function and cause endothelial damage in humans as well as in animal models\(^6,7\), showing that the endothelial monolayer is very sensitive to changes in plasma homocysteine levels.

Berberine (BBR), an isoquinoline alkaloid originally isolated from the Chinese herb *Coptis chinensis*, is an antimicrobial
drug routinely prescribed for the treatment of diarrhea in many Asian countries. In this form it is reported to exert antifungal, antibacterial/viral and anti-oncogenic effects, as well as a beneficial effect on diabetes, atherosclerosis and hyperlipidemia. Although protective effects of BBR have been observed in different animal models, the effects of BBR on HHCY-induced atherosclerotic plaque instability and the underlying mechanism are poorly understood. Here we reported that pharmacological activation of peroxisome proliferator-activated receptor-γ (PPARγ) by BBR increases atherosclerotic plaque stability in Apoe<sup>−/−</sup> mice with HHCY.

**MATERIALS AND METHODS**

**Materials**

BBR, GW9662, pyrrolidine dithiocarbamate (PDTC), dihydroethidium (DHE), apocynin, acetylecholine (Ach), sodium nitroprusside (SNP) and phenylephrine (PE) were purchased from Sigma Company (St. Louis, MO, USA). Commercial kits for determinations of malondialdehyde (MDA) and superoxide dismutase (SOD) activity were from Cayman Company (Ann Arbor, MI, USA).

**Animals and collar placement around carotid artery**

Apoe<sup>−/−</sup> mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA). Mice were housed in temperature-controlled cages with a 12-h light–dark cycle. The animal protocol was reviewed and approved by Jilin University Animal Care and Use Committee. As described previously, a constrictive silastic tube (0.30-mm inner diameter, 0.50-mm outer diameter and 2.5-mm long; Shandong Key Laboratory of Medical Polymer Materials, Jinan, China) was placed around the left common carotid artery near its bifurcation in male Apoe<sup>−/−</sup> mice at the age of 8–12 weeks.

**Determination of plaque vulnerable index**

The plaque vulnerable index was determined by using the ratio of CD68-positive (%) plus Oil Red (%) to α-actin (%) plus collagen (%) as described previously. Two different lesion areas were chosen to account for each segment, and the mean was used in statistical analysis.

**Cell culture**

As described previously, human umbilical vascular endothelial cells (HUVECs) from ATCC were grown in endothelial cells basal medium (Clonetics Inc., Walkersville, MD, USA) supplemented with 2% fetal bovine serum, penicillin (100 U/mL) and streptomycin (100 μg/mL). In all experiments, cells were between passages 3 and 8. All cells were incubated at 37°C in a humidified atmosphere of 5% CO₂ and 95% air. Cells were grown to 70–80% confluency before being treated with different agents.

**Organ chamber**

An organ chamber study was carried out as described previously. Mice were killed under anesthesia by intravenous injection with pentobarbital sodium (30 mg/kg). The descending aorta was isolated by removing the adhering perivascular tissue carefully, and was cut into rings (3–4 mm in length). Aortic rings were suspended and mounted to the organ chamber by using two stainless hooks. The rings were placed in organ baths filled with Krebs’ buffer of the following compositions (in mmol/L): NaCl, 118.3; KCl, 4.7; MgSO₄, 0.6; KH₂PO₄, 1.2; CaCl₂, 2.5; NaHCO₃, 25.0; ethylenediaminetetraacetic acid, 0.026; and pH 7.4 at 37°C, and gassed with 95% O₂ plus 5% CO₂, under a tension of 1.0 g, for a 90-min equilibration period. During this period, the Krebs’ solution was changed every 15 min. After the equilibration, aortic rings were challenged with 60 mmol/L KCl. After washing and another 30-min equilibration period, contractile response was elicited by PE (1 μmol/L). At the plateau of contraction, accumulative Ach (0.01, 0.03, 0.1, 0.3, 1, 3 μmol/L) or SNP (0.01, 0.03, 0.1, 0.3, 1, 3, 10 μmol/L) was added into the organ bath to induce endothelium-dependent or -independent relaxation.

For *ex vivo* experiments, the rings were contracted by PE (1 μmol/L) and then diluted with cumulative concentrations of Ach (0.01–3 μmol/L) to assess the integrity of the endothelium. The ring, which the maximal relaxation induced by Ach (3 μmol/L) was over 80%, was considered to have an intact endothelium and was used in the following study. Then, the rings were pretreated with BBR (10, 50, 100 μmol/L) for 30 min followed by the addition of HTL (1 mmol/L) for 90 min. After washing, Ach-induced endothelium-dependent relaxation and SNP-induced endothelium-independent relaxation were assayed, respectively. At the end of the experiments, the aortic rings were collected in liquid nitrogen for measurements of nitric oxide (NO) and MDA after being homogenized.

**Measurements of MDA content, SOD activity and NO level**

The contents of MDA content, SOD activity and NO level in aortic tissues or blood were assayed by using commercial kits following the recommend protocol as described previously.

**Evaluation of cell viability**

Cell viability was assayed by using methylthiazolyldiphenyltetrazolium bromide (MTT) as described previously. Cells were seeded onto a 96-well plate at the density of 10,000 cells/mL and incubated for 24 h. After treatment, 10 μL MTT (5 mg/mL) was added into cultured medium in each well for 2–4 h until purple precipitate was visible. After removal of culture medium, 75 μL dimethylsulfoxide was added to each well and the cells were left at room temperature in the dark for 2 h. Absorbance at 570 nm was recorded.

**Detection of reactive oxygen species**

Reactive oxygen species (ROS) production in cultured cells was assayed by measuring the DHE fluorescence as described previously. Briefly, before the end of treatment, 10 μmol/L DHE was added to the medium and incubated for 30 min at 37°C, then washed with phosphate-buffered saline twice. The image
was taken by fluorescent microscope. The DHE fluorescent intensity was recorded by a fluorescent reader at the wave of excitation (485 nm) and emission (545 nm). Control was set up as 100%.

**Statistical analysis**

Data are reported as mean ± SE of the mean. All data were analyzed with the use of one- or two-way ANOVA followed by multiple t-tests, and \( P < 0.05 \) were considered statistically significant.

**RESULTS**

**HHCY reduces atherosclerotic plaque stability in \( \text{Apoe}^{-/-} \) mice**

HHCY, as an independent risk factor of atherosclerosis, we first examined the effects of HHCY on the formation of prone-to-rupture plaque in advanced atherosclerosis, which is characterized by a thin fibrous cap, a large cholesterol deposition, rich in inflammatory cells and a few smooth muscle cells\(^{20}\). The HHCY model was induced by feeding \( \text{Apoe}^{-/-} \) mice with HTL as described previously\(^{17}\). We fed \( \text{Apoe}^{-/-} \) mice with HTL

![Figure 1](http://onlinelibrary.wiley.com/journal/jdi)
(50 mg/kg/day) for 8 weeks to mimic the model of HHCY. Treatment of mice with HTL dramatically increased plasma HTL levels, compared with control mice (7.38 ± 1.94 vs 2.91 ± 1.08 µmol/L, \( P < 0.01 \)). The plasma level of HCY (7.28 ± 2.12 vs 5.64 ± 1.73 µmol/L, \( P < 0.05 \)) was also slightly increased by treatment of HTL. These indexes showed that supplementation of HTL in the diet induced high blood levels of the HCY and HTL model in mice. The surgery of collar placement around the left common carotid artery was carried out to induce the formation of vulnerable plaque. As shown in Figure 1a–e, morphological and immunohistochemistry analysis showed that Oil Red\(^+\) lipid area and CD68\(^+\) area were significantly increased in mice fed with HTL, whereas Sirius Red\(^+\) collagen structures in atherosclerotic plaques were significantly decreased. The plaque vulnerable index was calculated according to the ratio of area I (Oil Red\(^+\)+CD68\(^+\)) to area II \([\alpha\text{-smooth muscle actin (SMA)}]+\text{collagen}^+\) as described previously\(^{21} \). Statistically, HTL dramatically increased the plaque vulnerable index in mice (Figure 1f).

**Figure 2** | Berberine (BBR) suppresses oxidative stress and improves endothelial functions in mice fed with homocysteine thiolactone (HTL) in vivo. The mice were intragastrically gavaged HTL (50 mg/kg/day) and received BBR (1.0 g/kg/day) for 8 weeks. At the end of the experiments, the mice were killed under anesthesia. The artery from the descending aorta was subjected to (a) endothelium-dependent relaxation induced by acetylcholine (Ach) assay and (b) endothelium-independent relaxation induced by sodium nitroprusside (SNP) in the organ chamber assay. Blood was collected to assay the serum level of (c) nitric oxide (NO) by the Griess method and (d) malondialdehyde (MDA) by the thiobarbituric acid method. All data are expressed as mean ± SE of the mean. Each group \( n = 5–10 \). *\( P < 0.05 \) vs control (Con), #\( P < 0.05 \) vs HTL alone.

**Administration of BBR increases plaque stability in HHCY mice**

We then determined the effects of BBR on the stability of advanced atherosclerotic plaque. As shown in Figure 1a–e, compared with HTL-fed mice, BBR significantly decreased the Oil Red\(^+\) lipid area and CD68\(^+\) macrophage area, and increased the Sirius Red\(^+\) collagen area, accompanied with the reduction of plaque vulnerable index (Figure 1f). Taking these data together, it suggests that BBR increases plaque stability in advanced vulnerable atherosclerosis in HHCY mice.

**Administration of BBR improves endothelial function in mice fed with HTL**

To investigate the mechanism of BBR on suppressing the formation of vulnerable atherosclerosis, we tested whether BBR improves vascular endothelial functions in mice with HHCY. Endothelial function was determined by measuring the vascular dilution induced by Ach. As shown in Figure 2a, HTL significantly inhibited Ach-induced vascular relaxation. Importantly,
the reduction of Ach-induced vascular relaxation was reversed by administration of BBR. Both HTL and BBR did not change SNP-induced vessel relaxation (Figure 2b), suggesting that the improvement of BBR on vascular bioactivity in HTL-fed mice is due to maintaining endothelial function.

Administration of BBR suppresses oxidative stress in mice fed with HTL

We also determined whether BBR preserves the normal redox state in HTL-fed mice. As expected, HTL induced the alternations, such as decreased serum NO level (Figure 2c) and increased serum levels of MAD (Figure 2d). All these defects induced by HTL were normalized by administration of BBR. This evidence indicate that the in vivo protective effects of BBR might be related to suppression of oxidative stress.

BBR through PPARγ preserves endothelium-dependent relaxation impaired by HTL in mice isolated aortic rings

We then examined how BBR suppressed oxidative stress and protected vascular endothelial functions. Exposure of the aortic ring to HTL dramatically impaired Ach-induced endothelium-dependent relaxation, which was reversed by BBR dose-dependently in aortic rings (Figure 3a). By using GW9662 of PPARγ antagonist22, we observed that BBR through PPARγ activation protects endothelial function. In addition, SNP-induced endothelium-independent relaxation was not altered in all groups (Figure 3c), suggesting that the protective effects produced by BBR on vascular function are limited to endothelium, but not vascular smooth muscle cells.

BBR through PPARγ preserves redox state in aortas, which is disturbed by HTL

Decreased NO bioavailability, which is as a result of decreased NO production or aberrant conversion of NO to ONOO⁻ by ROS, contributes to impairment of Ach-induced endothelium-dependent relaxation in the cardiovascular system23. We then examined whether HTL maintains a normal redox state in mouse isolated aortic rings. We found that HTL dramatically
decreased SOD activity (Figure 4a) and increased the content of MDA (Figure 4b), which is formed when ROS reacts with polyunsaturated fatty acid chain in membrane lipids. However, pretreatment of cells with GW9662 significantly abolished BBR-rescued abnormalities in HTL-incubated aortas, suggesting that BBR through PPARγ/ SOD-MDA reserves the normal balance of the anti-oxidative system.

BBR normalizes cell viabilities and oxidative stress in HTL-treated endothelial cells

We also investigated whether HTL affected cell viabilities in cultured HUVECs. As shown in Figure 5a, incubation of HUVECs with HTL (1 mmol/L) for 24 h dramatically reduced cell viabilities detected by MTT assay, consistent with previous reports. BBR alone did not affect endothelial cell viabilities, but dose-dependently reversed cell viabilities reduced by HTL.

We determined whether BBR through suppression of oxidative stress maintains the normal phenotypes of vascular endothelial cells. In Figure 5b and c, incubation of HUVECs with HTL (1 mmol/L) for 24 h remarkably increased ROS production in cultured cells. However, pre-incubation of these cells with BBR inhibited the enhancements of ROS production induced by HTL in a dose-dependent manner. Taking these together, it shows that BBR protects cell viabilities reduced by HTL, which is possibly related to suppression of oxidative stress.

BBR through PPARγ protects HTL-treated endothelial cells

Finally, we next determined whether BBR through activation of PPARγ provided beneficial effects in endothelial cells by using GW9662. As expected, inhibition of PPARγ by GW9662 significantly abolished the protective effects of BBR on the improvement of cell viabilities (Figure 6a), reductions of ROS production (Figure 6b,c) in a dose-dependent manner. Taking these data together, it shows that BBR through PPARγ activation suppresses oxidative stress and protects cell viability.

DISCUSSION

The present study first shows that HTL in vitro or in vivo causes accelerated oxidative stress, endothelial dysfunction and formation of atherosclerotic vulnerable plaque, all of which are abrogated by BBR. Mechanistically, the protective effect of BBR on vascular function is attributable to PPARγ activation, resulting in suppression of oxidative stress.

The major finding of the present study was that BBR through activation of PPARγ prevents HTL-induced endothelial dysfunctions. Recent studies have found that the conversion of homocysteine into HTL plays a critical role in the progress of cardiovascular diseases in patients with HHcy. In this present study, we used HTL to treat isolated aortic ring ex vivo or mice in vivo, by which both impaired Ach-induced endothelium-dependent relaxation, consistent with our previous study. This observation strongly supports the finding that the detrimental effects of homocysteine are related to the high reactivity of HTL, though the level of plasma thiolactone is very low. Most importantly, HTL-induced endothelial dysfunction both ex vivo and in vivo was reversed by BBR, which is in a dose-dependent manner. Collectively, the present results suggest that BBR functions as a protector of endothelial cells. This discovery is also supported by several published studies carried out in cultured endothelial cells or animals, which have shown that BBR protects endothelial function. However, a recent study on humans reported that BBR caused endothelial dysfunction in
normal volunteers. Of course, the reason for this discrepancy between healthy and HHCY requires further investigation.

Another finding of the present study is that BBR suppresses the formation of vulnerable plaque in advanced atherosclerosis. Previous studies have reported that BBR improved endothelial dysfunction and prevented atherosclerosis. In the present study, we further uncovered that BBR carried out its anti-oxidative action to increase plaque stability by providing in vitro, ex vivo or in vivo experimental evidence.

In summary, these studies support a novel function of BBR that activates PPARγ to suppress oxidative stress. This, in turn, leads to the improvement of endothelial function and atherosclerotic plaque stability. The finding that BBR attenuates endothelial dysfunction induced by HTL through suppression of oxidative stress could have broad applications for cardiovascular diseases, as endothelial dysfunction is a common characteristic at the beginning and in the progress of a number of vascular diseases including atherosclerosis and diabetes.
Thus, BBR might be a useful drug for more effective treatments of atherosclerosis and hypertension.

ACKNOWLEDGMENTS
This work was supported by the National Natural Science Foundation of China (81472030, 81472454, 31100930 and 81572082), Natural Science Foundation of Jilin Provincial Science and Technology Department, China (20150414015GH, 20110739 and 20150204001YY).

DISCLOSURE
The authors declare no conflict of interest.

REFERENCES
1. Chan CP, Rainer TH. Pathophysiological roles and clinical importance of biomarkers in acute coronary syndrome. Adv Clin Chem 2013; 59: 23–63.
2. Heeschen C. Biomarkers in acute coronary syndromes and their role in diabetic patients. Diab Vasc Dis Res 2005; 2: 122–127.
3. Hadi HA, Suwaidi JA. Endothelial dysfunction in diabetes mellitus. Vasc Health Risk Manag 2007; 3: 853–876.
4. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56: 111–128.
5. Malinowska J, Kolodziejczyk J, Olas B. The disturbance of hemostasis induced by hyperhomocysteinemia; the role of antioxidants. Acta Biochim Pol 2012; 59: 185–194.
6. Kolodziejczyk-Czepas J, Talar B, Nowak P, et al. Homocysteine and its thiolactone impair plasmin activity induced by urokinase or streptokinase in vitro. Int J Biol Macromol 2012; 50: 754–758.
7. Liu Y, Tian T, Zhang H, et al. The effect of homocysteine-lowering therapy with folic acid on flow-mediated vasodilation in patients with coronary artery disease: a meta-analysis of randomized controlled trials. Atherosclerosis 2014; 235: 31–35.
8. Affuso F, Mercurio V, Fazio V, et al. Cardiovascular and metabolic effects of Berberine. World J Cardiol 2010; 2: 71–77.
9. Mokhber-Dezfuli N, Saeidnia S, Gohari AR, et al. Phytochemistry and pharmacology of berberis species. Pharmacogn Rev 2014; 8: 8–15.
10. Wang Q, Zhang M, Liang B, et al. Activation of AMP-activated protein kinase is required for berberine-induced reduction of atherosclerosis in mice: the role of uncoupling protein 2. PLoS ONE 2011; 6: e25436.
11. Lau CW, Yao XQ, Chen ZY, et al. Cardiovascular actions of berberine. Cardiovasc Drug Rev 2001; 19: 234–244.
12. von der Thesen JH, van Berkel TJ, Biessen EA. Induction of rapid atherogenesis by perivascular carotid collar placement in apolipoprotein E-deficient and low-density lipoprotein receptor-deficient mice. Circulation 2001; 103: 1164–1170.
27. Liu YH, You Y, Song T, et al. Impairment of endothelium-dependent relaxation of rat aortas by homocysteine thiolactone and attenuation by captopril. J Cardiovasc Pharmacol 2007; 50: 155–161.

28. Wang Y, Huang Y, Lam KS, et al. Berberine prevents hyperglycemia-induced endothelial injury and enhances vasodilatation via adenosine monophosphate-activated protein kinase and endothelial nitric oxide synthase. Cardiovasc Res 2009; 82: 484–492.

29. Wang JM, Yang Z, Xu MG, et al. Berberine-induced decline in circulating CD31+/CD42– microparticles is associated with improvement of endothelial function in humans. Eur J Pharmacol 2009; 614: 77–83.

30. Cheng F, Wang Y, Li J, et al. Berberine improves endothelial function by reducing endothelial microparticles-mediated oxidative stress in humans. Int J Cardiol 2013; 167: 936–942.

31. Spinozzi S, Colliva C, Camborata C, et al. Berberine and its metabolites: relationship between physicochemical properties and plasma levels after administration to human subjects. J Nat Prod 2014; 77: 766–772.

32. Han Y, Wang Q, Song P, et al. Redox regulation of the AMP-activated protein kinase. PLoS ONE 2010; 5: e15420.

33. Antoniades C, Shirodaria C, Warrick N, et al. 5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation 2006; 114: 1193–1201.

34. Kawashima S, Yokoyama M. Dysfunction of endothelial nitric oxide synthase and atherosclerosis. Arterioscler Thromb Vasc Biol 2004; 24: 998–1005.

35. Alp NJ, Mussa S, Khoo J, et al. Tetrahydrobiopterin-dependent preservation of nitric oxide-mediated endothelial function in diabetes by targeted transgenic GTP-cyclohydrolase I overexpression. J Clin Invest 2003; 112: 725–735.